Levri Kara M, Slaymaker Elizabeth, Last Allen, Yeh Julie, Ference Jonathan, D'Amico Frank, Wilson Stephen A
University of Pittsburgh Medical Center St. Margaret, Pittsburgh, PA 15201, USA.
Ann Fam Med. 2005 Sep-Oct;3(5):457-61. doi: 10.1370/afm.343.
We wanted to determine whether metformin is an effective medication for treatment of overweight or obese adults who do not have diabetes mellitus or polycystic ovary syndrome (PCOS).
We searched MEDLINE (1966-2003), EMBASE (1986-2003), Allied and Complementary Medicine Database (1985-2003), International Pharmaceutical Abstracts (1970-2003), the Cochrane Library, American College of Physicians Journal Club, Database of Abstracts of Reviews of Effects, Cochrane Controlled Trials Register, MEDLINE In-Process & Other Non-Indexed Citations, reference lists of retrieved articles, and articles by selected authors and pharmaceutical manufacturers. Inclusion criteria were being obese or overweight determined by a BMI of 25 kg/m2 or greater or waist-to-hip ratio (WHR) of more than 0.8, metformin use, and aged 18 years or older. Exclusion criteria were a diagnosis of diabetes mellitus, polycystic ovarian syndrome or descriptors of polycystic ovarian syndrome, human immunodeficiency virus infection, and concomitant antipsychotic medications. Trials were graded on an 11-point Jadad scale. Only randomized controlled and blinded trials were accepted. Two reviewers independently extracted data from each trial. Primary outcomes measured were changes in BMI, WHR, and weight.
Fifty-seven potentially relevant studies were initially identified; 48 were excluded because of lack of randomization, lack of blinding, failure to meet inclusion or exclusion criteria, inaccessible outcomes, or improper study design. Nine clinical trials met criteria for validity assessment. Four studies used the parameter of waist-to-hip ratio, 3 studies included BMI, and 8 used weight. Two of the 9 studies showed a small reduction in WHR.
Insufficient evidence exists for the use of metformin as treatment of overweight or obese adults who do not have diabetes mellitus or polycystic ovary syndrome. Further studies are needed to answer this clinical question.
我们旨在确定二甲双胍对于无糖尿病或多囊卵巢综合征(PCOS)的超重或肥胖成年人是否为一种有效的治疗药物。
我们检索了MEDLINE(1966 - 2003年)、EMBASE(1986 - 2003年)、综合与补充医学数据库(1985 - 2003年)、国际药学文摘(1970 - 2003年)、考科蓝图书馆、美国医师学会杂志俱乐部、疗效评价文摘数据库、考科蓝对照试验注册库、MEDLINE在研及其他未索引引文、检索文章的参考文献列表以及选定作者和制药商的文章。纳入标准为通过体重指数(BMI)25kg/m²及以上或腰臀比(WHR)大于0.8确定为肥胖或超重、使用二甲双胍且年龄在18岁及以上。排除标准为患有糖尿病、多囊卵巢综合征或多囊卵巢综合征描述、人类免疫缺陷病毒感染以及同时使用抗精神病药物。试验根据11分的雅达评分法进行分级。仅接受随机对照和盲法试验。两名评审员独立从每个试验中提取数据。测量的主要结局为BMI、WHR和体重的变化。
最初识别出57项可能相关的研究;48项因缺乏随机化、缺乏盲法、未满足纳入或排除标准、无法获取结局或研究设计不当而被排除。9项临床试验符合有效性评估标准。4项研究使用腰臀比参数,3项研究纳入BMI,8项研究使用体重。9项研究中的2项显示WHR有小幅降低。
对于无糖尿病或多囊卵巢综合征的超重或肥胖成年人,使用二甲双胍治疗的证据不足。需要进一步研究来回答这个临床问题。